The Synairgen share price slumps! Here’s what I’d do now

The Synairgen share price has slumped following the publication of its latest trial results. This Fool isn’t planning to buy the decline.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Synairgen (LSE: SNG) share price has crumbled in value in early deals this morning. The stock is off nearly 8%, at the time of writing. 

To put this decline into perspective, over the past 12 months, shareholders have seen a return of 126%. Moreover, since the beginning of 2020, the stock has risen by more than 2,000%. 

However, past performance should never be used as a guide to future potential. Just because the Synairgen share price has produced considerable returns in the past doesn’t mean it’ll continue to outperform. 

That has become painfully clear today after the firm published results from its phase II trial of inhaled interferon beta in Covid-19 patients.

Positive results 

Today’s update from the business was a positive one. According to Richard Marsden, CEO of Synairgen, the trial findings show that the “SNG001 treatment led to a threefold likelihood of recovery to ‘no limitation of activities’ in the markedly/severely breathless population compared to those on placebo in the home and hospital setting.

SNG001 is Synairgen’s formulation containing interferon beta for nebulisation. This allows delivery directly into patients’ lungs.

Some studies have shown that Covid-19 suppresses the natural production of interferon beta. The virus can also prevent the induction of antiviral responses by infected cells. Synairgen’s work appears to show that its SNG001 formulation containing interferon beta can help overcome this problem. 

However, the company is still a long way from commercialising the product. The latest findings still need to be peer-reviewed. It’s also in the process of completing a phase III trial. After that, regulators will need to approve the product.

Considering the volume of work still required, there’s no guarantee this product will ever successfully make it to market. I think that’s the most significant risk overhanging the Synairgen share price right now. 

Synairgen share price decline 

It’s difficult to tell exactly why the Synairgen share price has declined so substantially today. However, it looks to me as if the market is starting to become concerned about the firm’s valuation. 

The company’s current market capitalisation stands at £308m, which seems to me to be a lot, considering the success of SNG001 is far from guaranteed. 

Of course, on the other hand, if the treatment successfully makes it through the next trial stage and is approved by medical regulators, the market could be substantial. In this best-case scenario, the Synairgen share price may be incredibly undervalued at current levels.

Despite this, I’m not a buyer of the stock today. I think the company’s future is incredibly uncertain. Until we have more information on the SNG001 treatment, there’s no guarantee whatsoever this will ever be a sustainable business.

This is just my own personal preference as I don’t like to invest in companies still in the development stage. However, other investors may be comfortable taking on this level of risk. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 26%, can the BT share price really push higher still?

The BT share price has surged on several catalysts in 2024, but there’s evidence to suggest that the stock could…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

What are the best dividend shares to buy right now?

As shares in B&M European Value Retail have fallen, the dividend yield has reached a 10-year high. Should investors be…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

My favourite FTSE 100 passive income stock that keeps the Christmas coffers full

The holiday season is expensive and can leave many consumers struggling to make ends meet. Here’s how I use a…

Read more »

Investing Articles

The latest growth forecasts suggest the Glencore share price will hit 555p!

Harvey Jones has been disappointed by the performance of the Glencore share price since he bought the commodity stock last…

Read more »

Dividend Shares

A closer look at the 11% dividend yield forecast for Phoenix Group shares

Phoenix Group shares have one of the highest dividend yields in the FTSE 100 index today. Could this be a…

Read more »

Investing Articles

If I’d put £25,000 into the FTSE 350 at the start of 2024, here’s how much I’d have today!

Many FTSE shares have rebounded this year as interest rates look set to keep heading lower and market appetite for…

Read more »

Investing Articles

Up 40%, but experts forecast the easyJet share price could soon hit 664p! Time to buy?

The easyJet share price has been flying lately and stock analysts are predicting more fun to come. But there's only…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

Worried about tax raids? Here’s how I’m targeting a £44,526 passive income with shares

Investing in a Self-Invested Personal Pension (SIPP) or Individual Savings Account (ISA) can supercharge one's passive income, says Royston Wild.

Read more »